泰山医学院学报
泰山醫學院學報
태산의학원학보
Journal of Taishan Medical College
2015年
9期
1007-1009
,共3页
玻璃体腔%曲安奈德%复方血栓通胶囊%糖尿病性黄斑水肿
玻璃體腔%麯安奈德%複方血栓通膠囊%糖尿病性黃斑水腫
파리체강%곡안내덕%복방혈전통효낭%당뇨병성황반수종
vitreous%triamcinolone acetonide%compound Xueshuantong capsule%diabetic macular edema
目的：探讨玻璃体腔注射曲安奈德联合复方血栓通胶囊治疗糖尿病性黄斑水肿的疗效。方法选取广州市白云区红十字会医院58例（108眼）糖尿病性黄斑水肿（ DME）患者为研究对象，采用简单抽样法随机分成治疗组（ A组）和对照组（ B组）两组，各54眼。其中A组采用玻璃体腔内注射曲安奈德联合复方血栓通胶囊口服，B组仅于玻璃体腔内注射曲安奈德。观察两组黄斑中心凹厚度（行光学相干断层成像检查测量）以及视力变化。结果①治疗3个月后，两组检查均较治疗前明显变薄，A组为（275.36±79.25）μm，明显薄于B组的（307.31±80.37）μm，P﹤0.05；治疗6个月后，A组持续变薄至（253.27±78.26）μm，B组则增厚至（362.26±81.47）μm，两组对比有统计学意义（P﹤0.05）；治疗6个月后，A组视力水平持续提升至（0.27±0.15），B组则降至（0.19±0.10），组间对比差异明显（ P﹤0.05）。结论对DME患者给予玻璃体腔注射曲安奈德联合复方血栓通胶囊方案，疗效较显著，值得临床推广。
目的：探討玻璃體腔註射麯安奈德聯閤複方血栓通膠囊治療糖尿病性黃斑水腫的療效。方法選取廣州市白雲區紅十字會醫院58例（108眼）糖尿病性黃斑水腫（ DME）患者為研究對象，採用簡單抽樣法隨機分成治療組（ A組）和對照組（ B組）兩組，各54眼。其中A組採用玻璃體腔內註射麯安奈德聯閤複方血栓通膠囊口服，B組僅于玻璃體腔內註射麯安奈德。觀察兩組黃斑中心凹厚度（行光學相榦斷層成像檢查測量）以及視力變化。結果①治療3箇月後，兩組檢查均較治療前明顯變薄，A組為（275.36±79.25）μm，明顯薄于B組的（307.31±80.37）μm，P﹤0.05；治療6箇月後，A組持續變薄至（253.27±78.26）μm，B組則增厚至（362.26±81.47）μm，兩組對比有統計學意義（P﹤0.05）；治療6箇月後，A組視力水平持續提升至（0.27±0.15），B組則降至（0.19±0.10），組間對比差異明顯（ P﹤0.05）。結論對DME患者給予玻璃體腔註射麯安奈德聯閤複方血栓通膠囊方案，療效較顯著，值得臨床推廣。
목적：탐토파리체강주사곡안내덕연합복방혈전통효낭치료당뇨병성황반수종적료효。방법선취엄주시백운구홍십자회의원58례（108안）당뇨병성황반수종（ DME）환자위연구대상，채용간단추양법수궤분성치료조（ A조）화대조조（ B조）량조，각54안。기중A조채용파리체강내주사곡안내덕연합복방혈전통효낭구복，B조부우파리체강내주사곡안내덕。관찰량조황반중심요후도（행광학상간단층성상검사측량）이급시력변화。결과①치료3개월후，량조검사균교치료전명현변박，A조위（275.36±79.25）μm，명현박우B조적（307.31±80.37）μm，P﹤0.05；치료6개월후，A조지속변박지（253.27±78.26）μm，B조칙증후지（362.26±81.47）μm，량조대비유통계학의의（P﹤0.05）；치료6개월후，A조시력수평지속제승지（0.27±0.15），B조칙강지（0.19±0.10），조간대비차이명현（ P﹤0.05）。결론대DME환자급여파리체강주사곡안내덕연합복방혈전통효낭방안，료효교현저，치득림상추엄。
Objective:To investigate the efficacy of intravitreal injection of triamcinolone acetonide combined with Fu-fang Xueshuantong Capsule in the treatment of diabetic macular edema. Methods:Fifty-eight patients(108 eyes)who met the diagnose criteria of diabetic macular edema( DME)were randomly divided into the treatment group( Agroup)and con-trol group( B group). The A group received intravitreal injection of triamcinolone acetonide combined with Fufang Xue-shuantong Capsule,group B only received intravitreal injection of triamcinolone acetonide. We observed the thickness( by optical coherence tomography measurements)and the changes of vision sight in both of the two groups. Results:After 3 months of treatment,two groups showed significantly change. The thickness in the group A(275. 36 ± 79. 25)μm was sig-nificantly thinner than that in group B(307. 31 ± 80. 37)μm,(P﹤0. 05);after 6 months of treatment,the thickness in the group A reduced to(253. 27 ± 78. 26)μm,while that in the group B was(362. 26 ± 81. 47)μm,the horizontal com-parison was statistically significant(P﹤0. 05);after 6 months treatment,vision sight level in the group A rose to(0. 27 ± 0. 15),which was much better than that of the group B(0. 19 ± 0. 10)(P﹤0. 05). Conclusion:The clinical efficiency of intravitreal injection of triamcinolone acetonide combined with Fufang Xueshuantong Capsule on patients with DME is re-markable,which is worth further clinical study and promotion.
